Aim: To see the efficacy of meglumine antimoniate alone in comparison with combination and CO2 ablative laser among patients cutaneous leishmaniasis. Study design: Quasi-experimental study. Place duration study: Department Dermatology, Pakistan Emirates Military Hospital, Rawalpindi from 9th July 2020 to 8th January 2021. Methodology: Sixty (30 each group) diagnosed cases leishmaniasis by skin ...

BACKGROUND Therapeutic response in infectious disease involves host as well as microbial determinants. Because the immune and inflammatory response to Leishmania (Viannia) species defines the outcome of infection and efficacy of treatment, immunomodulation is considered a promising therapeutic strategy. However, since Leishmania infection and antileishmanial drugs can themselves modulate drug t...

The favorable outcome of the treatment of a disease is influenced by the adherence to therapy. Our objective was to assess factors associated with adherence to treatment of patients included in a clinical trial of equivalence between the standard and alternative treatment schemes with meglumine antimoniate (MA) in the treatment of cutaneous leishmaniasis (CL), in the state of Rio de Janeiro. Be...

This study was a randomized, open label comparison that was designed to determine efficacy and safety of miltefosine as the first oral drug for the treatment of zoonotic cutaneous leishmaniasis caused by Leishmania major in comparison with meglumine antimoniate. Complete clinical response was defined as 100% re-epithelialization of the lesion. Definitions of lesion cure and failure were based o...

In a murine model of Leishmania infantum visceral leishmaniasis, metronidazole, ketoconazole, fluconazole, itraconazole, and terbinafine were less effective than antimonial agents in reducing hepatic parasite load. Ketoconazole potentiated the effect of meglumine antimoniate reference therapy through its marked activity against spleen infection.

INTRODUCTION Leishmaniasis is an important public health problem in the Americas. A Cochrane review published in 2009 analyzed 38 randomized controlled trials (RCT). We conducted a systematic review to evaluate the effects of therapeutic interventions for American cutaneous and mucocutaneous leishmaniasis. METHODS All studies were extracted from PubMed, Embase, Lilacs (2009 to July, 2012 resp...

the current treatment of choice for cutaneous leishmaniasis is either parenteral or intralesional antimonial compounds. each of these treatments has its own downfalls which include toxic side effects with the parentral injection and pain at the site of injection with the intralesional injection. in recent years, there has been more focus on paromomycin as an alternative drug; however, current d...

background cutaneous leishmaniasis (cl) is an endemic disease in iran. pentavalent antimonials including meglumine antimoniate (ma) are still the gold standard treatment. trichloroacetic acid (tca) is used in treatment of acne scar, photodamaged skin, and some other dermatologic diseases. considering the tca potential to induce collagen synthesis and its efficacy in the treatment of papular cl ...